Page last updated: 2024-12-07

n-acetylneuraminoyllactose

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3'-sialyllactose: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID123914
SCHEMBL ID8673965
MeSH IDM0040032
PubMed CID643987
SCHEMBL ID22259190
MeSH IDM0040032

Synonyms (80)

Synonym
a-neu5ac-(2>3)-b-d-gal-(1>4)-d-glc
(2>3')-a-sialyllactose
3'-monosialyllactose
35890-38-1
32-n-acetyl-a-neuraminyllactose
sialyllactose
a2,3-sialyllactose
3'-a-sialyllactose
3'-sialyl-d-lactose
3'-(n-acetyl-a-neuraminosyl)lactose
3'-n-acetylneuraminyl-d-lactose
d-glucose, o-5-(acetylamino)-3,5-dideoxy-d-glycero-a-d-galacto-2-nonulopyranonosyl-(2>3)-o-b-d-galactopyranosyl-(1>4)-
3'-sialyllactose
3'-sl
d-glucose, o-(n-acetyl-a-neuraminosyl)-(2>3)-o-b-d-galactopyranosyl-(1>4)- (9ci)
(2s,4s,5r,6r)-5-acetamido-2-[(2r,3s,4s,5r,6s)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,3r,4r,5r)-1,2,4,5-tetrahydroxy-6-oxohexan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1r,2r)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
3-sialyllactose
unii-3j7tal60g3
3j7tal60g3 ,
d-glucose, o-(n-acetyl-alpha-neuraminosyl)-(2->3)-o-beta-d-galactopyranosyl-(1->4)-
n-acetylneuraminoyllactose
AKOS015916417
neuramin lactose
32-n-acetyl-.alpha.-neuraminyllactose
n-acetyl-.alpha.-neuraminyl-(2 to 3')-lactose
sialyllactose [inci]
18409-13-7
3'-(n-acetyl-.alpha.-neuraminosyl)lactose
cylac 23
nan-lactose
d-glucose, o-(n-acetyl-.alpha.-neuraminosyl)-(2 to 3)-o-.beta.-d-galactopyranosyl-(1 to 4)-
.alpha.-2,3-sialyllactose
d-glucose, o-(n-acetyl-.alpha.-neuraminosyl)-(2.fwdarw.3)-o-.beta.-d-galactopyranosyl-(1.fwdarw.4)-
SCHEMBL8673965
W-202477
(2>3')-alpha-sialyllactose
alpha-neu5ac-(2>3)-beta-d-gal-(1>4)-d-glc
alpha-neu5ac-(2>3)-beta-delta-gal-(1>4)-delta-glc
Q3482888
(2s,4s,5r,6r)-5-acetamido-2-((2r,3s,4s,5r,6s)-3,5-dihydroxy-2-(hydroxymethyl)-6-((2r,3r,4r,5r)-1,2,4,5-tetrahydroxy-6-oxohexan-3-yloxy)tetrahydro-2h-pyran-4-yloxy)-4-hydroxy-6-((1r,2r)-1,2,3-trihydroxypropyl)tetrahydro-2h-pyran-2-carboxylic acid
DTXSID30905216
3'-n-acetylneuraminyl-d-lactose sodium slt
A918544
3mu-n-acetylneuraminyl-d-lactose sodium salt
gm3 ganglioside sugar
AS-82746
HY-108065
CS-0027263
35890-39-2
(2>6')-sialyllactose
6'-sialyllactose
6'-a-sialyllactose
(2>6')-a-sialyllactose
6'-monosialyllactose
d-glucose, o-(n-acetyl-a-neuraminosyl)-(2~6)-o-b-d-galactopyranosyl-(1~4)- (9ci)
d-glucose, o-5-(acetylamino)-3,5-dideoxy-d-glycero-alpha-d-galacto-2-nonulopyranonosyl-(2->6)-o-beta-d-galactopyranosyl-(1->4)-
(2r,4s,5r,6r)-5-acetamido-4-hydroxy-6-[(1r,2r)-1,2,3-trihydroxypropyl]-2-[[(2r,3r,4s,5r,6s)-3,4,5-trihydroxy-6-[(2r,3r,4r,5r)-1,2,4,5-tetrahydroxy-6-oxohexan-3-yl]oxyoxan-2-yl]methoxy]oxane-2-carboxylic acid
n-acetylneuramin-lactose
(2r,4s,5r,6r)-5-acetamido-4-hydroxy-2-{[(2r,3r,4s,5r,6s)-3,4,5-trihydroxy-6-{[(2r,3r,4r,5r)-1,2,4,5-tetrahydroxy-6-oxohexan-3-yl]oxy}oxan-2-yl]methoxy}-6-[(1r,2r)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
DTXSID40349248
6'-alpha-sialyllactose
(2>6')-alpha-sialyllactose
o-(n-acetyl-alpha-neuraminosyl)-(2-3)-o-beta-delta-galactopyranosyl-(1-4)-delta-glucose
o-(n-acetyl-alpha-neuraminosyl)-(2-3)-o-beta-d-galactopyranosyl-(1-4)-d-glucose
d-glucose, o-(n-acetyl-.alpha.-neuraminosyl)-(2->6)-o-.beta.-d-galactopyranosyl-(1->4)-
6'-.alpha.-sialyllactose
6'-n-gycolyneuraminyllactose
d-glucose, o-(n-acetyl-alpha-neuraminosyl)-(2->6)-o-beta-d-galactopyranosyl-(1->4)-
unii-lu9dta2whj
(2->6')-sialyllactose
LU9DTA2WHJ ,
(2r,4s,5r,6r)-5-acetamido-4-hydroxy-2-(((2r,3r,4s,5r,6s)-3,4,5-trihydroxy-6-(((2r,3r,4r,5r)-1,2,4,5-tetrahydroxy-6-oxohexan-3-yl)oxy)tetrahydro-2h-pyran-2-yl)methoxy)-6-((1r,2r)-1,2,3-trihydroxypropyl)tetrahydro-2h-pyran-2-carboxylic acid
SCHEMBL22259190
AS-78716
d-glucose,o-(n-acetyl-a-neuraminosyl)-(2?6)-o-b-d-galactopyranosyl-(1?4)-
d-glucose,o-(n-acetyl-a-neuraminosyl)-(26)-o-b-d-galactopyranosyl-(14)-
E80758
PD007009
HY-N10521
CS-0610211

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" There were no serious adverse reactions, such as life-threatening complications requiring hospitalization, causing disability, or causing deformity during the use of 6'-SL."( Randomized, triple-blind, placebo-controlled study to evaluate the safety of 6'-Sialyllactose in healthy adults.
Baek, A; Go, TH; Kang, DR; Kim, JH; Kim, SH; Yong, SY, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" To elucidate the pharmacokinetic characterization after oral administration to rats, the simultaneous quantification method for 3'-SL and 6'-SL in rat plasma was validated, using liquid chromatography-tandem mass spectrometry (LC-MS/MS) in an electrospray ionization (ESI) mode."( Simultaneous Quantification of 3'- and 6'-Sialyllactose in Rat Plasma Using Liquid Chromatography-Tandem Mass Spectrometry and Its Application to a Pharmacokinetic Study.
Eom, HY; Hwang, JH; Jang, SI; Kim, L; Lee, JH, 2021
)
0.62
" A pharmacokinetic study was performed with intravenous administration of 3'-SL and 6'-SL in minipigs (Sus scrofa/Yucatan)."( Development and validation of a bioanalytical method of analyzing 3'- and 6'-sialyllactose using liquid chromatography-tandem mass spectrometry in minipig plasma and its application in a pharmacokinetic study.
Eom, HY; Hwang, JH; Jang, SI; Kang, JS; Kim, L; Lee, JH, 2021
)
0.62
" To elucidate the pharmacokinetic characterization after oral administration to rats, the simultaneous quantification method for 3'-SL and 6'-SL in rat plasma was validated, using liquid chromatography-tandem mass spectrometry (LC-MS/MS) in an electrospray ionization (ESI) mode."( Simultaneous Quantification of 3'- and 6'-Sialyllactose in Rat Plasma Using Liquid Chromatography-Tandem Mass Spectrometry and Its Application to a Pharmacokinetic Study.
Eom, HY; Hwang, JH; Jang, SI; Kim, L; Lee, JH, 2021
)
0.62
" We performed a pilot clinical trial to analyze the pharmacokinetic properties of 6'-sialyllactose (6SL) and evaluated the safety, and efficacy of oral 6SL in patients with GNE myopathy."( Pharmacokinetics and clinical efficacy of 6'-sialyllactose in patients with GNE myopathy: Randomized pilot trial.
Choi, J; Go, H; Kim, L; Kim, MY; Park, DB; Park, E; Park, YE; Shin, JH; Sung, NJ, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (218)

TimeframeStudies, This Drug (%)All Drugs %
pre-199023 (10.55)18.7374
1990's35 (16.06)18.2507
2000's28 (12.84)29.6817
2010's87 (39.91)24.3611
2020's45 (20.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.76 (24.57)
Research Supply Index5.26 (2.92)
Research Growth Index5.02 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (1.60%)5.53%
Trials2 (3.57%)5.53%
Reviews6 (3.19%)6.00%
Reviews5 (8.93%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational1 (1.79%)0.25%
Other179 (95.21%)84.16%
Other48 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]